514 related articles for article (PubMed ID: 28476132)
1. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
[TBL] [Abstract][Full Text] [Related]
2. The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer.
Ueno T; Zenda S; Konishi T; Yurikusa T; Shibasaki Y; Nagamoto H; Fujii M
Int J Clin Oncol; 2019 Mar; 24(3):241-247. PubMed ID: 30426268
[TBL] [Abstract][Full Text] [Related]
3. Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis.
Chaitanya B; Pai KM; Yathiraj PH; Fernandes D; Chhaparwal Y
Oral Oncol; 2017 Sep; 72():179-182. PubMed ID: 28797456
[TBL] [Abstract][Full Text] [Related]
4. Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial).
Elsaadany B; Anayb SM; Mashhour K; Yossif M; Zahran F
BMC Oral Health; 2024 Jun; 24(1):645. PubMed ID: 38824583
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.
Yokota T; Hamauchi S; Yoshida Y; Yurikusa T; Suzuki M; Yamashita A; Ogawa H; Onoe T; Mori K; Onitsuka T
Support Care Cancer; 2018 Sep; 26(9):3241-3248. PubMed ID: 29627862
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy.
Yokota T; Tachibana H; Konishi T; Yurikusa T; Hamauchi S; Sakai K; Nishikawa M; Suzuki M; Naganawa Y; Hagihara T; Tsumaki H; Kubo T; Sato M; Taguri M; Morita S; Eguchi T; Kubota K; Zenda S
Support Care Cancer; 2016 Jul; 24(7):3029-36. PubMed ID: 26887378
[TBL] [Abstract][Full Text] [Related]
7. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Yen SH; Wang LW; Lin YH; Jen YM; Chung YL
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1463-70. PubMed ID: 21840136
[TBL] [Abstract][Full Text] [Related]
8. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.
Tsujimoto T; Yamamoto Y; Wasa M; Takenaka Y; Nakahara S; Takagi T; Tsugane M; Hayashi N; Maeda K; Inohara H; Uejima E; Ito T
Oncol Rep; 2015 Jan; 33(1):33-9. PubMed ID: 25351453
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis.
Akagi S; Fujiwara T; Nishida M; Okuda A; Nagao Y; Okuda T; Tokuda H; Takayanagi K
J Pharm Health Care Sci; 2019; 5():16. PubMed ID: 31367460
[TBL] [Abstract][Full Text] [Related]
10. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
Enami A; Masuda N; Yamamura J; Mizutani M; Yasojima H; Shikata A; Masaoka M; Takada S; Bamba N; Yamamoto M; Abe M; Makihara K
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1407-12. PubMed ID: 25434444
[TBL] [Abstract][Full Text] [Related]
12. Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.
Chung YL; Pui NNM
Support Care Cancer; 2017 Sep; 25(9):2743-2751. PubMed ID: 28353040
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effects of Adjuvant Melatonin in Minimizing Oral Mucositis Complications in Head and Neck Cancer Patients Receiving Concurrent Chemoradiation.
Onseng K; Johns NP; Khuayjarernpanishk T; Subongkot S; Priprem A; Hurst C; Johns J
J Altern Complement Med; 2017 Dec; 23(12):957-963. PubMed ID: 28657801
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.
Wu HG; Song SY; Kim YS; Oh YT; Lee CG; Keum KC; Ahn YC; Lee SW
Cancer; 2009 Aug; 115(16):3699-708. PubMed ID: 19514089
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Placebo-Controlled Study to Evaluate the Effect of Bio-Enhanced Turmeric Formulation on Radiation-Induced Oral Mucositis.
Soni TP; Gupta AK; Sharma LM; Singhal H; Sharma S; Gothwal RS
ORL J Otorhinolaryngol Relat Spec; 2022; 84(2):103-113. PubMed ID: 34161952
[TBL] [Abstract][Full Text] [Related]
16. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
17. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Rebamipide Gargle against Chemotherapy-induced Oral Mucositis].
Shinohara A; Nakamura M; Onikubo T; Nakamura K
Yakugaku Zasshi; 2015; 135(8):937-41. PubMed ID: 26234350
[TBL] [Abstract][Full Text] [Related]
20. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study.
Yasuda T; Chiba H; Satomi T; Matsuo A; Kaneko T; Chikazu D; Miyamatsu H
J Oral Maxillofac Res; 2012; 2(4):e3. PubMed ID: 24422000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
